lebrikizumab

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
Eli Lilly unveils new data from atopic dermatitis therapy trials
Eli Lilly unveils new data from atopic dermatitis therapy trials
Clinical Trials Arena
Eli Lilly
clinical trial
eczema
atopic dermatitis
lebrikizumab
Flag link:
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab
Flag link:
Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way
Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way
Medical Marketing and Media
Eli Lilly
donanemab
mirikizumab
lebrikizumab
pirtobrutinib
Flag link:
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Eli Lilly
lebrikizumab
Demira
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals
Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals
NASDAQ
Eli Lilly
lebrikizumab
monoclonal antibodies
atopic dermatitis
clinical trials
Flag link:
Lilly, swinging at the king, shows Dupixent rival works in phase 3, but wait for key figures goes on
Lilly, swinging at the king, shows Dupixent rival works in phase 3, but wait for key figures goes on
Fierce Biotech
Eli Lilly
lebrikizumab
Sanofi
Regeneron
Dupixent
atopic dermatitis
clinical trials
Flag link:
Lilly’s lebrikizumab looks to outdo Dupixent
Lilly’s lebrikizumab looks to outdo Dupixent
EP Vantage
Eli Lilly
lebrikizumab
atopic dermatitis
Dupixent
Sanofi
Regeneron
Flag link:
Why Dermira Stock Jumped Again Today
Why Dermira Stock Jumped Again Today
Motley Fool
Demira
lebrikizumab
atopic dermatitis
Flag link:
Dermira shares double on positive eczema data
Dermira shares double on positive eczema data
Biopharma Dive
Dermira
lebrikizumab
clinical trials
eczema
Flag link:
AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints
AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints
Endpoints
AstraZeneca
PD-1 inhibitors
asthma
tralokinumab
lebrikizumab
Flag link:
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Xconomy
Demira
Roche
eczema
lebrikizumab
Flag link:
Top asthma drug at Roche posts 1 win, 1 flop in identical PhIIIs
Top asthma drug at Roche posts 1 win, 1 flop in identical PhIIIs
Fierce Biotech
Roche
Genentech
asthma
clinical trials
lebrikizumab
Flag link:
Roche drug cuts asthma attacks, improves lung function -study
Roche drug cuts asthma attacks, improves lung function -study
Yahoo/Reuters
Roche
asthma
lebrikizumab
Flag link:
Roche CEO Schwan spotlights Roche's top three blockbuster hopefuls
Roche CEO Schwan spotlights Roche's top three blockbuster hopefuls
Fierce Biotech
Roche
Severin Schwan
Metmab
lung cancer
lebrikizumab
Pertuzumab
asthma
breast cancer
Flag link:
Roche asthma drug shows promise in mid-stage trial
Roche asthma drug shows promise in mid-stage trial
Reuters
Roche
asthma
lebrikizumab
Flag link: